MedTrace Logo

Anti-tumor Specific Immune Response in Head and Neck Cancers

NCT02881918 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 154

Last updated 2018-01-26

No results posted yet for this study

Summary

The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head \& Neck Squamous Cell Carcinoma

Secondary purposes are:

* Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs);
* Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS
* Study of relationship between anti-tumor immune response and clinical stage as well as DFS.

Conditions

Interventions

OTHER

Blood sample

Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Patrice GALLET · Service de ORL, Institut Louis Mathieu, CHRU de Nancy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-14
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02881918 on ClinicalTrials.gov